| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
hsa-miR-370-3p, hsa-miR-18a-5p |
| Biological function: |
Serves as a potential serum diagnostic biomarker for NSCLC; may regulate proliferative and metastasis processes; expression is correlated with T stage and lymphatic metastasis. |
| Molecular mechanism: |
Bioinformatics analysis suggested that circFOXP1 might bind hsa-miR-370-3p and hsa-miR-18a-5p and participate in VEGF signaling pathways regulating proliferation and metastasis. |
| Biological pathway or process: |
VEGF/VEGFR (promotes); proliferation (promotes); metastasis (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis; Transfection; Cohort Study |
| Clinical significance: |
Serum circFOXP1 has diagnostic potential for NSCLC, shows superior AUC compared with CEA and CYFRA21-1, and is significantly correlated with T stage and lymphatic metastasis. |
| Description: |
Serum circFOXP1 (hsa_circ_0008234) is significantly up-regulated in NSCLC and shows diagnostic value superior to CEA and CYFRA21-1 in this cohort. It is associated with T stage and lymphatic metastasis, and bioinformatics plus cell transfection/qRT-PCR analyses suggest that it may act through hsa-miR-370-3p and hsa-miR-18a-5p in VEGF-related proliferative and metastatic processes. |
| Confidence score: |
0.591 |